Coordination Chemistry of Novel Drug Candidates for the Treatment of Iron Overload

Iron overload is a serious clinical condition caused by excessive iron in the body, which can be largely prevented by the use of iron-specific chelating agents. At the moment there are only a few chelators in clinical use for the treatment of Fe overload. One of them, and so far the best working one...

Full description

Bibliographic Details
Main Author: Norin, Anneli
Format: Others
Language:English
Published: Mälardalens högskola, Institutionen för biologi och kemiteknik 2007
Subjects:
Online Access:http://urn.kb.se/resolve?urn=urn:nbn:se:mdh:diva-227
id ndltd-UPSALLA1-oai-DiVA.org-mdh-227
record_format oai_dc
spelling ndltd-UPSALLA1-oai-DiVA.org-mdh-2272013-01-08T13:47:26ZCoordination Chemistry of Novel Drug Candidates for the Treatment of Iron OverloadengNorin, AnneliMälardalens högskola, Institutionen för biologi och kemiteknikInstitutionen för biologi och kemiteknik2007Chemical engineeringKemiteknikIron overload is a serious clinical condition caused by excessive iron in the body, which can be largely prevented by the use of iron-specific chelating agents. At the moment there are only a few chelators in clinical use for the treatment of Fe overload. One of them, and so far the best working one, is desferrioxamine (DFO). This iron chelator has a major disadvantage of being orally inactive and is given by long and frequent subcutaneous infusions (12-24 hours/5-6 days/week) to patients. 1 Consequently, the design of an orally active, nontoxic, selective iron chelator has become a high priority. To design an iron chelator for clinical use, the important factors to consider are metal selectivity and affinity, ligand-metal complex stability, bioavailability and toxicity. The best iron chelator should be highly selective for iron(III) in order to minimize chelation of other biological essential metal ions which could lead to deficiency with prolonged usage. Favouring the Fe (III) oxidation state avoids Fenton chemistry and the production of toxic free radicals. This report deals with complexes of aroylpicolylhydrazines. Chemical and biological testing has established that these molecules function extremely well as iron chelators in vivo. The most effective candidates are more efficient at promoting iron efflux (release of iron) from cells than the existing drug DFO. Although the ligands discussed in this report, are selective for iron, there is no record of how they interact with other essential metal ions (Mn, Co, Ni, Cu and Zn) in our body and it is this that is the topic of this report. It was found that the complexes with H2PPH (N,N’-bis(α-picolinoyl)hydrazine) probably built polymeric complexes and therefore they were almost totally insoluble in all common solvents. The complexes of H2BPH (N-(benzoyl)-N’-(picolinoyl)hydrazine)) were also problematic in terms of insolubility. Another problem was decomposition of the complexes in solution, with resultant precipitation of the ligand and that happened with all of the ligands. The ligand H2TPH formed complexes with Ni and Co, [MII(HL)2] and [MIII(L)2]-, and crystals were grown suitable for x-ray structure studies. The cobalt complex is the first one reported of its kind. There was also crystals grown suitable for x-ray work of a protonated picolylhydrazide and that is also the first crystal structure reported. Student thesisinfo:eu-repo/semantics/bachelorThesistexthttp://urn.kb.se/resolve?urn=urn:nbn:se:mdh:diva-227application/pdfinfo:eu-repo/semantics/openAccess
collection NDLTD
language English
format Others
sources NDLTD
topic Chemical engineering
Kemiteknik
spellingShingle Chemical engineering
Kemiteknik
Norin, Anneli
Coordination Chemistry of Novel Drug Candidates for the Treatment of Iron Overload
description Iron overload is a serious clinical condition caused by excessive iron in the body, which can be largely prevented by the use of iron-specific chelating agents. At the moment there are only a few chelators in clinical use for the treatment of Fe overload. One of them, and so far the best working one, is desferrioxamine (DFO). This iron chelator has a major disadvantage of being orally inactive and is given by long and frequent subcutaneous infusions (12-24 hours/5-6 days/week) to patients. 1 Consequently, the design of an orally active, nontoxic, selective iron chelator has become a high priority. To design an iron chelator for clinical use, the important factors to consider are metal selectivity and affinity, ligand-metal complex stability, bioavailability and toxicity. The best iron chelator should be highly selective for iron(III) in order to minimize chelation of other biological essential metal ions which could lead to deficiency with prolonged usage. Favouring the Fe (III) oxidation state avoids Fenton chemistry and the production of toxic free radicals. This report deals with complexes of aroylpicolylhydrazines. Chemical and biological testing has established that these molecules function extremely well as iron chelators in vivo. The most effective candidates are more efficient at promoting iron efflux (release of iron) from cells than the existing drug DFO. Although the ligands discussed in this report, are selective for iron, there is no record of how they interact with other essential metal ions (Mn, Co, Ni, Cu and Zn) in our body and it is this that is the topic of this report. It was found that the complexes with H2PPH (N,N’-bis(α-picolinoyl)hydrazine) probably built polymeric complexes and therefore they were almost totally insoluble in all common solvents. The complexes of H2BPH (N-(benzoyl)-N’-(picolinoyl)hydrazine)) were also problematic in terms of insolubility. Another problem was decomposition of the complexes in solution, with resultant precipitation of the ligand and that happened with all of the ligands. The ligand H2TPH formed complexes with Ni and Co, [MII(HL)2] and [MIII(L)2]-, and crystals were grown suitable for x-ray structure studies. The cobalt complex is the first one reported of its kind. There was also crystals grown suitable for x-ray work of a protonated picolylhydrazide and that is also the first crystal structure reported.
author Norin, Anneli
author_facet Norin, Anneli
author_sort Norin, Anneli
title Coordination Chemistry of Novel Drug Candidates for the Treatment of Iron Overload
title_short Coordination Chemistry of Novel Drug Candidates for the Treatment of Iron Overload
title_full Coordination Chemistry of Novel Drug Candidates for the Treatment of Iron Overload
title_fullStr Coordination Chemistry of Novel Drug Candidates for the Treatment of Iron Overload
title_full_unstemmed Coordination Chemistry of Novel Drug Candidates for the Treatment of Iron Overload
title_sort coordination chemistry of novel drug candidates for the treatment of iron overload
publisher Mälardalens högskola, Institutionen för biologi och kemiteknik
publishDate 2007
url http://urn.kb.se/resolve?urn=urn:nbn:se:mdh:diva-227
work_keys_str_mv AT norinanneli coordinationchemistryofnoveldrugcandidatesforthetreatmentofironoverload
_version_ 1716528795518763008